Caris Life Sciences, Inc.

Compare

109 Followers

CAI Stock Chart & Stats

$29.43

Market closed

$29.43

Day’s Range― - ―

52-Week Range$25.40 - $42.50

Previous CloseN/A

VolumeN/A

Average Volume (3M)728.28K

Market Cap

$8.86B

Enterprise Value$7.21B

Total Cash (Recent Filing)$721.18M

Total Debt (Recent Filing)$418.98M

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Aug 12, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Sep 09, 2021

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding281,224,120

10 Day Avg. Volume691,794

30 Day Avg. Volume728,283

Financial Highlights & Ratios

PEG Ratio-0.52

Price to Book (P/B)-2.85

Price to Sales (P/S)17.30

P/FCF Ratio-28.11

Enterprise Value/Market Cap0.81

Enterprise Value/Revenue23.84

Enterprise Value/Gross Profit42.21

Enterprise Value/Ebitda-55.90

Forecast

1Y Price Target

$40.33

Price Target Upside37.04% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Market PositionCaris is the leading tissue-based CGP player with a pipeline of tests across MRD and MCED coming, with superior revenue and margin gains forecasted.

Regulatory ApprovalRecent FDA approval of Caris Life Sciences' tissue-based therapy selection assay as a Companion Diagnostic is expected to catalyze profitability.

Revenue GrowthCaris Life Sciences is expected to grow its top-line at a 33% compound annual growth rate from 2025 to 2028 and reach positive adjusted EBITDA by the end of 2025, ramping to a 35.8% adjusted EBITDA margin by 2028.

Bears Say

Premium ValuationCaris is trading at a premium valuation due to its strong financial profile and near-term path to profitability.

Stock VolatilityA High Risk rating is assigned due to the current lack of profitability and early-stage commercial payer conversations for rate increases, leading to stock volatility.

Caris Life Sciences, Inc. News

Caris Life Sciences announces collaborative new research on TET2

Caris Life Sciences (CAI) announced collaborative new research identifying TET2 clonal hematopoiesis, or CH, as a promising biomarker...

2d ago

CAI

Caris Life Sciences added to ‘Tactical Outperform’ list at Evercore ISI

Evercore ISI analyst Vijay Kumar added Caris Life Sciences (CAI) to the firm’s “Tactical Outperform” list. The stock...

24d ago

CAI

Caris Life Sciences publishes study in Oncotarget on MI Cancer Seek

Caris Life Sciences (CAI) has published a study in Oncotarget validating the analytical and clinical performance of MI...

3M ago

CAI

Caris Life Sciences publishes results of antibody-drug study in breast cancer

Caris Life Sciences (CAI) published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two...

3M ago

CAI

Caris Life Sciences price target raised to $45 from $38 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on Caris Life Sciences (CAI) to $45 from $38...

3M ago

CAI

Caris Life Sciences price target raised to $42 from $34 at Citi

Citi raised the firm’s price target on Caris Life Sciences (CAI) to $42 from $34 and keeps a...

3M ago

CAI

Caris Life Sciences Reports Strong Q2 2025 Results

Caris Life Sciences, Inc. ( ($CAI) ) has released its Q2 earnings. Here is a breakdown of the...

3M ago

CAI

Strong Performance and Growth Potential: Caris Life Sciences, Inc. Receives Buy Rating with Increased Price Target

Analyst Daniel Brennan of TD Cowen maintained a Buy rating on Caris Life Sciences, Inc., boosting the price...

3M ago

CAI

Closing Bell Movers: CoreWeave down 10% despite revenue beat, guidance raise

In the opening hour of the evening session, U.S. equity futures are little changed, with lacking follow through...

3M ago

CAI

DIS

Caris Life Sciences reports Q2 EPS ($7.97) with items, consensus (22c)

Reports Q2 revenue $181.4M, consensus $137.67M. Reports Q2 net loss $71.8M, including $37.1M of one-time expense associated with...

3M ago

CAI

Caris Life Sciences sees FY25 revenue $675.0M-$685.0M, consensus $588M

Clinical therapy selection volume is expected to be in the growth range of 19%-21% compared to FY24. Published...

3M ago

CAI

Private Markets: Canva draws attention as IPO candidate following Figma debut

Canva is gaining significant attention as a potential IPO candidate. The rising investor enthusiasm around the design-software giant...

3M ago

CAI

TER, NVDA, AMD: Cathie Wood Makes Million-Dollar Bets on AI and Robotics

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made million-dollar bets in the artificial intelligence (AI) and robotics sectors on July...

3M ago

AMD

CAI

ROKU, ACHR: Cathie Wood Offloads Millions in Roku and Archer Aviation Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several interesting trades on Monday, July 14. The ace hedge fund manager...

4M ago

CAI

ACHR

CAI FAQ

What was Caris Life Sciences, Inc.’s price range in the past 12 months?

Caris Life Sciences, Inc. lowest stock price was $25.40 and its highest was $42.50 in the past 12 months.

What is Caris Life Sciences, Inc.’s market cap?

Caris Life Sciences, Inc.’s market cap is $8.86B.

When is Caris Life Sciences, Inc.’s upcoming earnings report date?

Caris Life Sciences, Inc.’s upcoming earnings report date is Aug 12, 2025 which is 80 days ago.

How were Caris Life Sciences, Inc.’s earnings last quarter?

Caris Life Sciences, Inc. released its earnings results on Aug 12, 2025. The company reported -$7.97 earnings per share for the quarter, missing the consensus estimate of -$0.218 by -$7.752.

Is Caris Life Sciences, Inc. overvalued?

According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Caris Life Sciences, Inc. pay dividends?

Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here

What is Caris Life Sciences, Inc.’s EPS estimate?

Caris Life Sciences, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Caris Life Sciences, Inc. have?

Caris Life Sciences, Inc. has 281,224,120 shares outstanding.

What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?

Caris Life Sciences, Inc. reported an EPS of -$7.97 in its last earnings report, missing expectations of -$0.218. Following the earnings report the stock price went up 5.607%.

Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?

Currently, no hedge funds are holding shares in CAI

Caris Life Sciences, Inc. Stock Smart Score

Neutral

Company Description

Caris Life Sciences, Inc.

Caris Life Sciences, Inc. is a leading biotechnology company that specializes in molecular intelligence and precision medicine. The company operates primarily in the healthcare sector, focusing on cancer diagnostics and treatment optimization through advanced genomic and proteomic profiling. Caris offers a range of services, including its flagship Caris Molecular Intelligence platform, which provides comprehensive tumor profiling to help healthcare providers determine the most effective therapies for individual patients based on their unique tumor characteristics.

Caris Life Sciences, Inc. (CAI) Earnings & Revenues

Historic Earnings Reports

CAI Company Deck

CAI Earnings Call

Q2 2025

0:00 / 0:00

CAI Stock 12 Month Forecast

Average Price Target

$40.33

▲(37.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","46":"$46","30.25":"$30.3","35.5":"$35.5","40.75":"$40.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,30.25,35.5,40.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.33,31.45846153846154,32.58692307692308,33.715384615384615,34.84384615384615,35.972307692307695,37.10076923076923,38.22923076923077,39.357692307692304,40.48615384615385,41.614615384615384,42.74307692307693,43.871538461538464,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.33,31.09923076923077,31.86846153846154,32.637692307692305,33.40692307692308,34.176153846153845,34.94538461538461,35.714615384615385,36.48384615384615,37.25307692307692,38.02230769230769,38.79153846153846,39.56076923076923,{"y":40.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.33,30.84307692307692,31.356153846153845,31.869230769230768,32.38230769230769,32.895384615384614,33.40846153846154,33.92153846153846,34.434615384615384,34.94769230769231,35.46076923076923,35.973846153846154,36.48692307692308,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.25,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >